NURS 658 Discussion: High-Alert Medications
DQ2 Review the ISMP List of High-Alert Medications in Acute
Care Settings document at this link:
https://www.ismp.org/tools/highalertmedications.pdf
Complete a search for one of the medications from the ISMP
lList. Discuss your findings (e.g., a search for “digoxin” returns one element
in “ingredient,” three elements in Brand Name, four elements in dose form
group, and 10 elements of “Clinical Drug or Pack”). Share your findings.
You can use
https://www.nlm.nih.gov/research/umls/rxnorm/overview.html as an additional
reference.
ORDER NOW FOR AN ORIGINAL NURSING ESSAY ASSIGNMENT ON: NURS 658 Discussion: High-Alert Medications
High-alert medications are drugs that bear a heightened risk of causing significant patient harm when they are used in error. Although mistakes may or may not be more common with these drugs, the consequences of an error are clearly more devastating to patients.Use ISMP’s List of High-Alert Medications in Acute Care Settings to determine which medications in your organization require special safeguards to reduce the risk of errors and minimize harm. Strategies may include:
Standardizing the ordering, storage, preparation, and administration of these medications
Improving access to information about these drugs
Limiting access to high-alert medications
Using auxiliary labels and automated alerts
Employing redundancies
The nurse’s primary role in the medication process is to ensure that drugs are administered safely to patients, thus reducing the risk of unnecessary harm or injury. High-alert medications are a particular concern for healthcare professionals, since they are associated with an increased risk of causing patient harm. This article identifies high-risk medications and outlines measures that can be used to prevent potential harm to patients as a result of these medications, including computerised provider order entry, Tall Man lettering, order sets, independent double-checks and proactive patient monitoring.
Discussion:High-Alert Medications NURS 658
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO
licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).
Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the
work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses
any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you
must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you
should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health
Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall
be the binding and authentic edition”.
Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the
World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules).
Suggested citation. Medication Safety in High-risk Situations. Geneva: World Health Organization;
2019 (WHO/UHC/SDS/2019.10). Licence: CC BY-NC-SA 3.0 IGO.
Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for
commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures
or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from
the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests
solely with the user.
Discussion:High-Alert Medications NURS 658
General disclaimers. The designations employed and the presentation of the material in this publication do not imply the
expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or
of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent
approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or
recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted,
the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the
published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the
interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use